Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Signs Of Improving FDA Inspection Outcomes At Indian Sites But Long Road Ahead

Executive Summary

Moving up the manufacturing compliance curve is still a work in progress for several Indian firms, but there appear to be some early signs that US FDA inspection outcomes, in general, may have improved.

Related Content

Aurobindo Injectables Unit Falls Foul Of FDA But Analysts Hopeful
Sun’s Key Halol Plant Flunks FDA Inspection Again
Ex-US FDA Official Sklamberg On Park Doctrine Limits, Data Integrity
Bayer In FDA's Bad Books Over Facility Failures
Data Integrity Failures Undermine Trust That Can’t Easily Be Won Back, EMA Official Says
Indian CEOs On Plugging Quality Gaps: Yes We Can


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts